366 related articles for article (PubMed ID: 31136750)
1. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
Front Immunol; 2021; 12():808964. PubMed ID: 35095898
[TBL] [Abstract][Full Text] [Related]
3. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
4. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Quiroga D; Lyerly HK; Morse MA
Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
7. The colorectal cancer immune microenvironment and approach to immunotherapies.
Koi M; Carethers JM
Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
[No Abstract] [Full Text] [Related]
8. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
10. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
[TBL] [Abstract][Full Text] [Related]
11. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
Shen Y; Guan Y; Hummel JJ; Shyu CR; Mitchem JB
BMC Cancer; 2020 Feb; 20(1):124. PubMed ID: 32059711
[TBL] [Abstract][Full Text] [Related]
12. Advancing Immunotherapy in Metastatic Breast Cancer.
Mansour M; Teo ZL; Luen SJ; Loi S
Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
[TBL] [Abstract][Full Text] [Related]
13. Facts and Hopes in Colorectal Cancer Immunotherapy.
Foote MB; Argilés G; Rousseau B; Segal NH
Clin Cancer Res; 2023 Oct; 29(20):4032-4039. PubMed ID: 37326624
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
Linette GP; Carreno BM
Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
16. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
17. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
Link JT; Overman MJ
Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
[TBL] [Abstract][Full Text] [Related]
19. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
[TBL] [Abstract][Full Text] [Related]
20. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
Guo L; Wang C; Qiu X; Pu X; Chang P
Front Immunol; 2020; 11():1052. PubMed ID: 32547556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
